# US 2017/0362251 A1 · Phosphoinositide 3-kinase inhibitors with a zinc binding moiety

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0362251 A1
- Document ID: US20170362251A1
- Status: Published application
- Kind: A1
- Application number: 15/637,448
- Filed: 2017-06-29
- Published: 2017-12-21
- Earliest claimed: 2009-01-08
- Assignees: Curis, Inc.
- Applicants: Curis, Inc.
- Inventors: Xiong Cai; Haixiao Zhai; Chengjung Lai; Chenggeng Qian
- Web page: https://patentgrep.com/patent/US20170362251A1

## CPC

- C07D 495/04: Ortho-condensed systems
- A61K 31/535: having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 5/14: of the thyroid hormones, e.g. T3, T4
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/08: of the prostate
- A61P 13/10: of the bladder
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/00: Drugs for dermatological disorders
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 413/14: containing three or more hetero rings
- C07D 491/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The instant application relates to deazapurines, thienopyrimidines and furopyrimidines with zinc-binding moiety based derivatives and their use in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer. The instant application further relates to the treatment of histone deacetylase related disorders and diseases related to both histone deacetylase and phosphoinositide 3-kinase.

## Claims

### Claim 1

A compound represented by formula (I);
or a geometric isomer, enantiomer, diastereomer, racemate, pharmaceutically acceptable salt, or prodrug thereof,
wherein represents a single or double bond;
q, r and s are independently 0 or 1, wherein at least one of q, r and s is 1;
t is 0 or 1;
n is 0, 1, 2, 3 or 4;
p is 0, 1 or 2;
X and Y are independently CR1, N(R8), S or O, wherein when one of X and Y is CR1, the other is N(R8), S or O;
G1 is CR1, S, O, NR10 or NS(O)2R10;
G2 is substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl or, substituted or unsubstituted heterocyclic;
G3 is substituted or unsubstituted C1-C8 alkyl, substituted or unsubstituted C2-C8 alkenyl, or, substituted or unsubstituted C2-C8 alkynyl;
each R8 is independently hydrogen, acyl, aliphatic or substituted aliphatic;
each R1 and R2 is independently selected from absent, hydrogen, hydroxy, amino, halogen, alkoxy, alkylamino, dialkylamino, CF3, CN, NO2, sulfonyl, acyl, aliphatic, substituted aliphatic, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic;
Ra is optionally substituted alkyl, optionally substituted aryl or optionally substituted heteroaryl;
Rb is hydrogen, optionally substituted alkyl, optionally substituted aryl or optionally substituted heteroaryl;
or Ra and Rb, together with the nitrogen atom to which they are attached, form an optionally substituted heterocyclic group;
R10 is selected from hydrogen, hydroxy, amino, alkoxy, alkylamino, dialkylamino, sulfonyl, acyl, aliphatic, substituted aliphatic, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic;
B is a linker; and
C is selected from:
where W is O or S; J is O, NH or NCH3; and R31 is hydrogen or lower alkyl;
where W is O or S; Y2 is absent, N, or CH; Z is N or CH; R32 and R34 are independently hydrogen, hydroxy, aliphatic group, provided that if R32 and R34 are both present, one of R32 or R34 must be hydroxy and if Y2 is absent, R34 must be hydroxy; and R33 is hydrogen or aliphatic group;
where W is O or S; Y1 and Z1 are independently N, C or CH; and
where Z, Y2, and W are as previously defined; R11 and R12 are independently selected from hydrogen or aliphatic; R21, R22 and R23 are independently selected from hydrogen, hydroxy, amino, halogen, alkoxy, alkylamino, dialkylamino, CF3, CN, NO2, sulfonyl, acyl, aliphatic, substituted aliphatic, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic.

### Claim 2 (depends on 1)

A compound of claim 1, wherein B is selected from the group consisting of straight chain C1-C10 alkyl, C1-C10 alkenyl, C1-C10 alkynyl, alkoxy, alkoxyC1-C10alkoxy, C1-C10 alkylamino, alkoxyC1-C10alkylamino, C1-C10 alkylcarbonylamino, C1-C10 alkylaminocarbonyl, aryloxyC1-C10alkoxy, aryloxyC1-C10alkylamino, aryloxyC1-C10alkylamino carbonyl, C1-C10-alkylaminoalkylaminocarbonyl, alkyl(N-alkyl)aminoalkyl-aminocarbonyl, alkylaminoalkylamino, alkylcarbonylaminoalkylamino, alkyl(N-alkyl)aminoalkylamino, (N-alkyl)alkylcarbonylaminoalkylamino, alkylaminoalkyl, alkylaminoalkylaminoalkyl, alkylpiperazinoalkyl, piperazinoalkyl, alkylpiperazino, alkenylaryloxyC1-C10alkoxy, alkenylarylaminoC1-C10alkoxy, alkenylaryllalkylaminoC1-C10alkoxy, alkenylaryloxyC1-C10alkylamino, alkenylaryloxyC1-C10alkylaminocarbonyl, piperazinoalkylaryl, heteroarylC1-C10alkyl, heteroarylC2-C10alkenyl, heteroarylC2-C10alkynyl, heteroarylC1-C10alkylamino, heteroarylC1-C10alkoxy, heteroaryloxyC1-C10alkyl, heteroaryloxyC2-C10alkenyl, heteroaryloxyC2-C10alkynyl, heteroaryloxyC1-C10alkylamino and heteroaryloxyC1-C10alkoxy.

### Claim 3 (depends on 1)

A compound of claim 1, represented by formula (II):
wherein X, Y, G1, G2, R1, R2, R8, n, p, q, r, s, B and C are as defined as in claim 1.

### Claim 4 (depends on 3)

A compound of claim 3, wherein G2 is optionally substituted phenyl, pyridyl, pyrimidyl, indazolyl, pyrrolyl or benzimidazolyl.

### Claim 5 (depends on 4)

A compound of claim 4, wherein G2 is a phenyl, pyridyl, pyrimidyl, indazolyl, pyrrolyl or benzimidazolyl group, wherein said group is substituted by a hydroxyl, hydroxymethyl, amino, acylamino, acetylamino or methylamino group.

### Claim 6 (depends on 1)

A compound of claim 1, represented by formula (IV), (V), (VI) or (VII);
or the geometric isomers, enantiomers, diastereomers, racemates, pharmaceutically acceptable salts, or prodrugs thereof,
wherein represents a single or double bond;
G1, G2, R1, R2, R8, n, p, q, r, s, B and C are as defined as in claim 1;
m is 0, 1, 2 or 3;
G4 is NR8, S or O;
R3 is selected from absent, hydrogen, hydroxy, amino, halogen, alkoxy, alkylamino, dialkylamino, CF3, CN, NO2, sulfonyl, acyl, aliphatic, substituted aliphatic, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic.

### Claim 7 (depends on 6)

A compound of claim 6, wherein G2 is selected from the group below:
wherein R3, R8 and m have the meanings set forth in claim 6.

### Claim 8 (depends on 7)

A compound of claim 7, wherein m is 1 and R3 is selected from the group consisting of hydroxy, hydroxymethyl, amino, acylamino, acetylamino and methylamino.

### Claim 9 (depends on 1)

A compound of claim 1, represented by formula (XIV), (XV), (XVI) or (XVII);
wherein G1, G2, n, p, B, C, R1, R2, and R8 are as defined in claim 1;
m is 0, 1, 2 or 3; and
R3 is selected from absent, hydrogen, hydroxy, amino, halogen, alkoxy, alkylamino, dialkylamino, CF3, CN, NO2, sulfonyl, acyl, aliphatic, substituted aliphatic, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic.

### Claim 10 (depends on 6, 9)

A compound of claim 9, wherein G2 is selected from the group below:
wherein R3, R8 and m have the meanings set forth in claim 6.

### Claim 11 (depends on 10)

A compound of claim 10, wherein m is 1 and R3 is selected from the group consisting of hydroxy, hydroxymethyl, amino, acylamino, acetylamino and methylamino.

### Claim 12 (depends on 1)

A compound of claim 1, wherein B is selected from:
wherein d and e are independently 0, 1, 2, 3, 4, 5, 6, 7 or 8; and R100 is selected from hydrogen, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl and C3-C8 cycloalkyl.

### Claim 13 (depends on 1)

A compound of claim 1, represented by formula XX or XXI;
wherein n, m, p, Y2, W, Z, G1, G2, G4, R1, R2, R3, R8, R32, R33 and R34 are as defined in claim 1;
G4 is NR8, S or O;
m is 0, 1, 2 or 3;
R3 is selected from absent, hydrogen, hydroxy, amino, halogen, alkoxy, alkylamino, dialkylamino, CF3, CN, NO2, sulfonyl, acyl, aliphatic, substituted aliphatic, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic;
M1 is absent, O, S, NR8, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, heteroaryl, heterocyclic, SO, SO2 or C═O; M2 is absent, C1-C6 alkyl, O, NR8, heterocyclic, aryl, heteroaryl, or C═O; M3 is absent, O, NR8, S, SO, SO2, CO, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, heteroaryl, or heterocyclic; M4 is absent, O, NR8, heteroaryl, heterocyclic or aryl; and M5 is absent, C1-C8 alkyl, C2-C8 alkenyl, C2-C8alkynyl, heteroaryl, heterocyclic or aryl.

### Claim 14 (depends on 1)

A compound of claim 1, represented by formula XXII or XXIII;
wherein G1, G2, n, p, R1, R2, R3, R8 are as defined in claim 1;
t, v and w are independently 0, 1, 2 or 3;
u is 0, 1, 2, 3, 4, 5, 6, 7 or 8;
m is 0, 1, 2 or 3;
G4 is NR8, S or O;
G5 is absent, C1-C8 alkyl or a C1-C8 alkyl interrupted by one or more O, S, S(O), SO2, N(R8), C(O);
G6 is selected from CR1 or NR8;
G7 is selected from —CR1, S or O; and
R5 and R6 are independently selected from absent, hydrogen, hydroxy, amino, halogen, alkoxy, alkylamino, dialkylamino, CF3, CN, NO2, sulfonyl, acyl, aliphatic, substituted aliphatic, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic.

### Claim 15 (depends on 1)

A compound according to claim 1 selected from the compounds delineated in Table A or a geometric isomer, enantiomer, diastereomer, racemate, pharmaceutically acceptable salt, or prodrug thereof:
TABLE A
Compound No.
Structure
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215

### Claim 16 (depends on 1)

A pharmaceutical composition comprising as an active ingredient a compound of claim 1 and a pharmaceutical acceptable carrier.

### Claim 17 (depends on 15)

A method of treating a PI3K related disease or disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 15.

### Claim 18 (depends on 15)

A method of treating an mTOR-mediated disease comprising administering to a subject in need thereof a pharmaceutical composition of claim 15.

### Claim 19 (depends on 15)

A method of treating an HDAC-mediated disease comprising administering to a subject in need thereof a pharmaceutical composition of claim 15.

### Claim 20 (depends on 15)

A method of treating both PI3K and HDAC mediated diseases comprising administering to a subject in need thereof a pharmaceutical composition of claim 15.
